Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics (Nasdaq: TMDX) signed a long-term lease for a new global headquarters at Assembly Innovation Park in Somerville, Massachusetts, and acquired an adjacent land parcel to create an integrated campus. The facility will house corporate, R&D, and advanced manufacturing functions with a planned relocation on or before January 2028. The Commonwealth proposed performance-based incentives of up to $18 million tied to creating as many as 600 net new full-time jobs from 2026–2031. Somerville offered up to $18 million in TIF tax relief and projects $75 million in new local tax revenue over ten years.
TransMedics (Nasdaq: TMDX) said members of its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST. The presentation will be available live and as an archived webcast on the company’s Investors website. The company also noted its standard investor presentation is available at the same link.
TransMedics (Nasdaq: TMDX) announced inducement equity grants dated Dec 22, 2025 for five new employees under Nasdaq Listing Rule 5635(c)(4) and the TransMedics Inducement Plan.
The company granted an aggregate of 6,333 non-qualified stock options and 4,205 restricted stock units (RSUs). The options carry a per-share exercise price of $129.35 (closing price on Dec 22, 2025) and a 10-year term. Option vesting: 25% on first anniversary of start date, remainder monthly over the next three years, subject to continued service. RSU vesting: 25% on each of the first four anniversaries of the start date, subject to continued service. Grants were approved by the Compensation Committee.
TransMedics (NASDAQ:UDMY) announced a strategic collaboration with Mercedes-Benz to deploy a purpose-built Mercedes-Benz V-Class fleet and establish four Italian National OCS Program (NOP) hubs in Milan, Rome, Padua, and Bari, with launches expected before the end of 2025.
Each hub will be equipped with OCS Lung, Heart, and Liver Systems, staffed by clinical perfusionists, and supported by a National Command Center in Santa Giulia, Milan, to provide 24/7 technological, clinical, and logistical support aimed at increasing donor organ utilization across Italy.
TransMedics (Nasdaq: TMDX) announced management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York.
The event is scheduled for Tuesday, December 2, 2025 at 9:30 a.m. ET at the Lotte New York Palace. A live and archived webcast will be available on the company's Investors website and the standard investor presentation is posted at the same link.
TransMedics (Nasdaq: TMDX) on October 27, 2025 granted inducement equity awards to 15 new employees under Nasdaq Listing Rule 5635(c)(4) and the TransMedics Inducement Plan. The company granted non-qualified stock options to purchase an aggregate of 27,582 shares and 18,299 restricted stock units.
Options carry a $132.45 per-share exercise price (closing price on October 27, 2025), a 10-year term, and vest 25% after one year with the remainder vesting monthly over the next three years. RSUs vest 25% on each of the first four anniversaries of employment, each subject to continued service and plan terms.
TransMedics (Nasdaq: TMDX) reported third quarter 2025 results on October 29, 2025, with Q3 revenue of $143.8 million, up 32% year‑over‑year, and net income of $24.3 million or $0.66 per diluted share. Gross margin was 59% and operating expenses were $61.3 million. Cash totaled $466.2 million as of September 30, 2025. The company owns 21 aircraft as of September 30, 2025 and 22 as of October 29, 2025, and announced a strategic collaboration with Mercedes‑Benz to deploy dedicated organ-transport vehicles in Italy. TransMedics raised and narrowed its full‑year 2025 revenue guidance to $595 million–$605 million.
TransMedics (Nasdaq:TMDX) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
The TransMedics management team will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT; domestic dial-in is (844) 676-6010 and international dial-in is (412) 634-6944. A live and archived webcast will be available in the Investors section at https://investors.transmedics.com/.
TransMedics (NASDAQ: TMDX) has announced a strategic collaboration with Mercedes-Benz to establish Italy's first dedicated organ transplantation ground transportation network. The initiative will deploy specially equipped Mercedes-Benz V-Class vehicles across four National OCS Program (NOP) hubs in Milan, Rome, Padua, and Bari.
The network will support TransMedics' Organ Care System (OCS) perfusion technology and will be operational by the end of 2025. Each hub will be equipped with OCS Lung, Heart, and Liver Systems and staffed with clinical perfusionists, providing 24/7 support to transplant centers. The Italian National Command Center will be based in Santa Giulia, Milan.
This collaboration marks TransMedics' first step in replicating its successful U.S. NOP model in Europe, potentially laying the groundwork for a broader European transplant logistics network.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two upcoming investor conferences in New York this September.
Management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 10:00 a.m. EST, followed by a presentation at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 12:15 p.m. EST. Both presentations will be available via webcast on the company's investor relations website.
FAQ
What is the current stock price of Transmedics Group (TMDX)?
What is the market cap of Transmedics Group (TMDX)?
